Johnson & Johnson files to end Schering-Plough relationship - Philadelphia Business Journal:

erofeyporgrinin.blogspot.com
Remicade generated sales of $2.8 billion last year for of Horsham, Pa. Schering-Plough, of Kenilworth, posted revenue of more than $2 billion from Remicade sales last Simponi wasjust OK’d by the Food and Drug Administrationm last month. In its arbitration Johnson & Johnson of New Brunswick, N.J., is seekingv a ruling that the proposesd mergerof (NYSE:MRK) and Schering-Plough constitutes a change of control that would permit the terminatiobn of the agreements. Merck and Schering-Plougjh structured their deal as a reverse merger to avoid triggeringthe change-of-controk provision.
In the filing earlier this monthy with the Securities andExchange Commission, Mercik and Schering-Plough said they will “vigorously any Centocor effort to end the distributionj pact.